Mather Group’s Inhibikase Therapeutics IKT Stock Holding History

Mather Group’s Portfolio IKT Stock Details IKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-334	Closed	-$721	–	1935
2024 Q2	$721	Buy	+334	New	+$576	﹤0.01%	2030

Other funds holding IKT

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Mather Group's IKT Position: Q3 2024 in Review

Mather Group sold out of Inhibikase Therapeutics (IKT) in Q3 2024, closing a stake of 334 shares — an estimated $721 sold.

Mather Group first reported a position in IKT in Q2 2024 and held it in 1 quarter. The position peaked at $721 in Q2 2024. 11 funds tracked by Wall St. Rank hold IKT as of Q3 2024.

Mather Group reported no remaining Inhibikase Therapeutics position as of Q3 2024 after selling out during the quarter.
Mather Group sold 334 Inhibikase Therapeutics shares in Q3 2024, an estimated $721.
Mather Group first reported a position in Inhibikase Therapeutics in Q2 2024 and held it in 1 quarter.
Mather Group's Inhibikase Therapeutics position peaked at $721 in Q2 2024.
11 funds tracked by Wall St. Rank held Inhibikase Therapeutics as of Q3 2024.

Based on Mather Group's 13F filing for Q3 2024, filed 7 Oct 2024.